Biohaven Pharmaceutical Holding Company Ltd. Aktie News
8,31 $
2,85 %
NYSE,
14. November, 22:11 Uhr
tracken
Biohaven Pharmaceutical Holding Company Ltd. Aktie News
Neutral
PRNewsWire
●
4 Tage alt
NEW HAVEN, Conn. , Nov. 13, 2025 /PRNewswire/ -- Biohaven Ltd.
Positiv
Seeking Alpha
●
5 Tage alt
Biohaven (BHVN) narrows focus to three late-stage clinical programs and implements cost-cutting to address heavy R&D spending and steep share price declines. BHVN's pipeline includes Opakalim for depression and epilepsy, TRAP/MoDE degraders for IgA nephropathy and Graves' disease, and Taldefgrobep alfa for obesity and spinal muscular atrophy. Despite intriguing science and large market opportun...
Neutral
PRNewsWire
●
5 Tage alt
NEW HAVEN, Conn. , Nov. 12, 2025 /PRNewswire/ -- Biohaven Ltd.
Neutral
PRNewsWire
●
6 Tage alt
NEW HAVEN, Conn. , Nov. 11, 2025 /PRNewswire/ -- Biohaven Ltd.
Neutral
PRNewsWire
●
7 Tage alt
NEW HAVEN, Conn. , Nov. 10, 2025 /PRNewswire/ -- Biohaven Ltd.
Negativ
Reuters
●
12 Tage alt
Shares of Biohaven fell more than 40% on Wednesday after the U.S. Food and Drug Administration declined to approve its experimental treatment for a rare brain disorder.
Negativ
Investors Business Daily
●
12 Tage alt
Biohaven stock cratered Wednesday after the FDA rejected the company's treatment for an inherited neurodegenerative disease.
Neutral
PRNewsWire
●
12 Tage alt
The troriluzole clinical development program encompassed the first industry clinical trials to generate data showing therapeutic potential in patients with spinocerebellar ataxia (SCA), a rare genetic, inherited, life-threatening neurodegenerative disease with no treatment options. Compelling data from troriluzole's new drug application (NDA) included: a 3-year real-world evidence study (Study ...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
